Staurosporine allows dystrophin expression by skipping of nonsense-encoding exon

Brain and Development

Volumn 38, Issue 8, 2016, Pages 738-745

  Nishida, Atsushi ^a,b   Oda, Ayaka ^a,c   Takeuchi, Atsuko ^c   Lee, Tomoko ^d   Awano, Hiroyuki ^e   Hashimoto, Naohiro ^f   Takeshima, Yasuhiro ^d   Matsuo, Masafumi ^a  

^a KOBE GAKUIN UNIVERSITY   (Japan)

^b JCR Pharmaceuticals Co   (Japan)

^c KOBE PHARMACEUTICAL UNIVERSITY   (Japan)

^d HYOGO COLLEGE OF MEDICINE   (Japan)

^e KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

Author keywords

Chemical; Dystrophin; Exon skipping; Nonsense mutation; Staurosporine

Indexed keywords

DYSTROPHIN; ENZASTAURIN; MESSENGER RNA; MIDOSTAURIN; PHOSPHOTRANSFERASE INHIBITOR; STAUROSPORINE; TG 003; UNCLASSIFIED DRUG; CLK DUAL-SPECIFICITY KINASES; DESMIN; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; STOP CODON;

ARTICLE; CDC LIKE KINASE 1 GENE; CONTROLLED STUDY; CULTURE MEDIUM; EXON SKIPPING; GENE; GENE AMPLIFICATION; GENETIC TRANSFECTION; HELA CELL LINE; HUMAN; HUMAN CELL; IMMORTALIZED CELL LINE; MUSCLE CELL; NONSENSE MUTATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; WILD TYPE; EXON; METABOLISM; STOP CODON;

CODON, NONSENSE; DESMIN; DYSTROPHIN; EXONS; HELA CELLS; HUMANS; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; STAUROSPORINE; TRANSFECTION;

EID: 84961778327     PISSN: 03877604     EISSN: 18727131     Source Type: Journal    
DOI: 10.1016/j.braindev.2016.03.003     Document Type: Article

References (31)

1. [1] Wood, M.J., Gait, M.J., Yin, H., RNA-targeted splice-correction therapy for neuromuscular disease. Brain 133 (2010), 957–972.
2. [2] Disterer, P., Kryczka, A., Liu, Y., Badi, Y.E., Wong, J.J., Owen, J.S., et al. Development of therapeutic splice-switching oligonucleotides. Hum Gene Ther 25 (2014), 587–598.
3. [3] Oltean, S., Modulators of alternative splicing as novel therapeutics in cancer. World J Clin Oncol 6 (2015), 92–95.
4. [4] Mendell, J.R., Rodino-Klapac, L.R., Sahenk, Z., Roush, K., Bird, L., Lowes, L.P., et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol 74 (2013), 637–647.
5. [5] Voit, T., Topaloglu, H., Straub, V., Muntoni, F., Deconinck, N., Campion, G., et al. Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol 13 (2014), 987–996.
6. [6] Matsuo, M., Takeshima, Y., Nishio, H., Contributions of Japanese patients to development of antisense therapy for DMD. Brain Dev 38 (2016), 4–9.
7. [7] Matsuo, M., Duchenne/Becker muscular dystrophy: from molecular diagnosis to gene therapy. Brain Dev 18 (1996), 167–172.
8. [8] Aartsma-Rus, A., van Ommen, G.J., Less is more: therapeutic exon skipping for Duchenne muscular dystrophy. Lancet Neurol 8 (2009), 873–875.
9. [9] Goemans, N.M., Tulinius, M., van den Akker, J.T., Burm, B.E., Ekhart, P.F., Heuvelmans, N., et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 364 (2011), 1513–1522.
10. [10] Cirak, S., Arechavala-Gomeza, V., Guglieri, M., Feng, L., Torelli, S., Anthony, K., et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 378 (2011), 595–605.
11. [11] Hoffman, E., A rebirth for drisapersen in Duchenne muscular dystrophy?. Lancet Neurol 13 (2014), 963–965.
12. [12] O'Leary, D.A., Sharif, O., Anderson, P., Tu, B., Welch, G., Zhou, Y., et al. Identification of small molecule and genetic modulators of AON-induced dystrophin exon skipping by high-throughput screening. PLoS One, 4, 2009, e8348.
13. [13] Hu, Y., Wu, B., Zillmer, A., Lu, P., Benrashid, E., Wang, M., et al. Guanine analogues enhance antisense oligonucleotide-induced exon skipping in dystrophin gene in vitro and in vivo. Mol Ther 18 (2010), 812–818.
14. [14] Nishida, A., Kataoka, N., Takeshima, Y., Yagi, M., Awano, H., Ota, M., et al. Chemical treatment enhances skipping of a mutated exon in the dystrophin gene. Nat Commun, 2, 2011, 308.
15. [15] Ahn, A.H., Kunkel, L.M., The structural and functional diversity of dystrophin. Nat Genet 3 (1993), 283–291.
16. [16] Zhang, Z., Habara, Y., Nishiyama, A., Oyazato, Y., Yagi, M., Takeshima, Y., et al. Identification of seven novel cryptic exons embedded in the dystrophin gene and characterization of 14 cryptic dystrophin exons. J Hum Genet 52 (2007), 607–617.
17. [17] Shiga, N., Takeshima, Y., Sakamoto, H., Inoue, K., Yokota, Y., Yokoyama, M., et al. Disruption of the splicing enhancer sequence within exon 27 of the dystrophin gene by a nonsense mutation induces partial skipping of the exon and is responsible for Becker muscular dystrophy. J Clin Invest 100 (1997), 2204–2210.
18. [18] Nishiyama, A., Takeshima, Y., Saiki, K., Narukage, A., Oyazato, Y., Yagi, M., et al. Two novel missense mutations in the myostatin gene identified in Japanese patients with Duchenne muscular dystrophy. BMC Med Genet 8 (2007), 1–9.
19. [19] Flanigan, K.M., Dunn, D.M., von Niederhausern, A., Soltanzadeh, P., Howard, M.T., Sampson, J.B., et al. Nonsense mutation-associated Becker muscular dystrophy: interplay between exon definition and splicing regulatory elements within the DMD gene. Hum Mutat 32 (2011), 299–308.
20. [20] Omura, S., Sasaki, Y., Iwai, Y., Takeshima, H., Staurosporine, a potentially important gift from a microorganism. J Antibiot (Tokyo) 48 (1995), 535–548.
21. [21] Park, B.S., Abdel-Azeem, A.Z., Al-Sanea, M.M., Yoo, K.H., Tae, J.S., Lee, S.H., Staurosporine analogues from microbial and synthetic sources and their biological activities. Curr Med Chem 20 (2013), 3872–3902.
22. [22] Kamachi, M., Aramaki, T., Tanimura, S., Ichinose, K., Fujikawa, K., Iwamoto, N., et al. Activation of protein phosphatase causes alternative splicing of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): potential effect on immune surveillance. Biochem Biophys Res Commun 360 (2007), 280–285.
23. [23] Xiao, Q., Ford, A.L., Xu, J., Yan, P., Lee, K.Y., Gonzales, E., et al. Bcl-x pre-mRNA splicing regulates brain injury after neonatal hypoxia-ischemia. J Neurosci 32 (2012), 13587–13596.
24. [24] Shiomi, K., Kiyono, T., Okamura, K., Uezumi, M., Goto, Y., Yasumoto, S., et al. CDK4 and cyclin D1 allow human myogenic cells to recapture growth property without compromising differentiation potential. Gene Ther 18 (2011), 857–866.
25. [25] Habara, Y., Doshita, M., Hirozawa, S., Yokono, Y., Yagi, M., Takeshima, Y., et al. A strong exonic splicing enhancer in dystrophin exon 19 achieve proper splicing without an upstream polypyrimidine tract. J Biochem 143 (2008), 303–310.
26. [26] Muraki, M., Ohkawara, B., Hosoya, T., Onogi, H., Koizumi, J., Koizumi, T., et al. Manipulation of alternative splicing by a newly developed inhibitor of CLKs. J Biol Chem 279 (2004), 24246–24254.
27. [27] Jurica, M.S., Moore, M.J., Pre-mRNA splicing: awash in a sea of proteins. Mol Cell 12 (2003), 5–14.
28. [28] Wahl, M.C., Will, C.L., Luhrmann, R., The spliceosome: design principles of a dynamic RNP machine. Cell 136 (2009), 701–718.
29. [29] Stamm, S., Regulation of alternative splicing by reversible protein phosphorylation. J Biol Chem 283 (2008), 1223–1227.
30. [30] Yomoda, J., Muraki, M., Kataoka, N., Hosoya, T., Suzuki, M., Hagiwara, M., et al. Combination of CLK family kinase and SRp75 modulates alternative splicing of Adenovirus E1A. Genes Cells 13 (2008), 233–244.
31. [31] Eisenreich, A., Bogdanov, V.Y., Zakrzewicz, A., Pries, A., Antoniak, S., Poller, W., et al. Cdc2-like kinases and DNA topoisomerase I regulate alternative splicing of tissue factor in human endothelial cells. Circ Res 104 (2009), 589–599.